Characterizing Variability in Lung Cancer Outcomes and Influence of a Lung Diagnostic Assessment Program in Southeastern Ontario, Canada

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2023 May 26

PMID 37232826

Authors

Shahad Alghamdi

Weidong Kong

Michael Brundage

Elizabeth A Eisenhauer

Christopher M Parker

Genevieve C Digby

Affiliations

Soon will be listed here.

Abstract

Introduction: Regional variability in lung cancer (LC) outcomes exists across Canada, including in the province of Ontario. The Lung Diagnostic Assessment Program (LDAP) in southeastern (SE) Ontario is a rapid-assessment clinic that expedites the management of patients with suspected LC. We evaluated the association of LDAP management with LC outcomes, including survival, and characterized the variability in LC outcomes across SE Ontario.

Methods: We conducted a population-based retrospective cohort study by identifying patients with newly diagnosed LC through the Ontario Cancer Registry (January 2017-December 2019) and linked to the LDAP database to identify LDAP-managed patients. Descriptive data were collected. Using a Cox model approach, we compared 2-year survival for patients managed through LDAP vs. non-LDAP.

Results: We identified 1832 patients, 1742 of whom met the inclusion criteria (47% LDAP-managed and 53% non-LDAP). LDAP management was associated with a lower probability of dying at 2 years (HR 0.76 vs. non-LDAP, < 0.0001). Increasing distance from the LDAP was associated with a lower likelihood of LDAP management (OR 0.78 for every 20 km increase, < 0.0001). LDAP-managed patients were more likely to receive specialist assessment and undergo treatments.

Conclusions: In SE Ontario, initial diagnostic care provided via LDAP was independently associated with improved survival in patients with LC.

Citing Articles

Factors Influencing the Timeliness and Completeness of Appropriate Staging Investigations for Patients with Stage I-III Lung Cancer in Southeastern Ontario.

Alghamdi S, Ahimsadasan N, Kong W, Brundage M, Eisenhauer E, Parker C Curr Oncol. 2024; 31(10):6073-6084.

PMID: 39451757 PMC: 11505813. DOI: 10.3390/curroncol31100453.

Pathways to cancer care after a suspected cancer diagnosis in the emergency department: a survey of emergency physicians across Ontario.

Grewal K, Thompson C, Ovens H, Sutradhar R, Savage D, Borgundvaag B CJEM. 2024; 26(12):865-874.

PMID: 39373854 DOI: 10.1007/s43678-024-00787-0.

The emergency department is no place to be told you have cancer.

Grewal K, Varner C CMAJ. 2024; 196(18):E626-E627.

PMID: 38740414 PMC: 11090632. DOI: 10.1503/cmaj.240612.

Improving Access to Care, Patient Costs, and Environmental Impact Through a Community Outreach Lung Cancer Rapid Assessment Clinic.

Golemiec B, Robertson M, Poon V, Foley M, Parker C, McGann C JCO Oncol Pract. 2024; 20(8):1123-1131.

PMID: 38696740 PMC: 11368164. DOI: 10.1200/OP.23.00657.

References

Kobayashi S, Suzuki S, Niikawa H, Sugawara T, Yanai M . Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPD. Respirology. 2009; 14(5):675-9. DOI: 10.1111/j.1440-1843.2009.01543.x. View

Mullin M, Tran A, Golemiec B, Stone C, Noseworthy C, OCallaghan N . Improving Timeliness of Lung Cancer Diagnosis and Staging Investigations Through Implementation of Standardized Triage Pathways. JCO Oncol Pract. 2020; 16(10):e1202-e1208. PMC: 7564135. DOI: 10.1200/JOP.19.00807. View

Stone C, Vaid H, Selvam R, Ashworth A, Robinson A, Digby G . Multidisciplinary Clinics in Lung Cancer Care: A Systematic Review. Clin Lung Cancer. 2018; 19(4):323-330.e3. DOI: 10.1016/j.cllc.2018.02.001. View

Detterbeck F, Boffa D, Kim A, Tanoue L . The Eighth Edition Lung Cancer Stage Classification. Chest. 2016; 151(1):193-203. DOI: 10.1016/j.chest.2016.10.010. View

Stone C, Robinson A, Brown E, Mates M, Falkson C, Owen T . Improving Timeliness of Oncology Assessment and Cancer Treatment Through Implementation of a Multidisciplinary Lung Cancer Clinic. J Oncol Pract. 2019; 15(2):e169-e177. DOI: 10.1200/JOP.18.00214. View

Chadha A, Ganti A, Sohi J, Sahmoun A, Mehdi S . Survival in untreated early stage non-small cell lung cancer. Anticancer Res. 2005; 25(5):3517-20. View

Dela Cruz C, Tanoue L, Matthay R . Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011; 32(4):605-44. PMC: 3864624. DOI: 10.1016/j.ccm.2011.09.001. View

Shin S, Shin S, Im Y, Lee G, Jeong B, Lee K . Effect of perioperative bronchodilator therapy on postoperative pulmonary function among lung cancer patients with COPD. Sci Rep. 2021; 11(1):8359. PMC: 8052420. DOI: 10.1038/s41598-021-86791-1. View

Mullin M, Shellenberger J, Whitehead M, Brundage M, Eisenhauer E, Lougheed M . Characterizing Regional Variability in Lung Cancer Outcomes across Ontario-A Population-Based Analysis. Curr Oncol. 2022; 29(12):9640-9659. PMC: 9777041. DOI: 10.3390/curroncol29120757. View

10.

Brocken P, van der Heijden E, Oud K, Bootsma G, Groen H, Donders A . Distress in suspected lung cancer patients following rapid and standard diagnostic programs: a prospective observational study. Psychooncology. 2014; 24(4):433-41. DOI: 10.1002/pon.3660. View

11.

Su S, Hu Y, Ouyang W, Ma Z, Lu B, Li Q . The survival outcomes and prognosis of stage IV non-small-cell lung cancer treated with thoracic three-dimensional radiotherapy combined with chemotherapy. Radiat Oncol. 2014; 9:290. PMC: 4278263. DOI: 10.1186/s13014-014-0290-7. View

12.

Stone C, Johnson A, Robinson D, Katyukha A, Egan R, Linton S . Health Resource and Cost Savings Achieved in a Multidisciplinary Lung Cancer Clinic. Curr Oncol. 2021; 28(3):1681-1695. PMC: 8161784. DOI: 10.3390/curroncol28030157. View

13.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

14.

Wao H, Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B . Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Syst Rev. 2013; 2:10. PMC: 3579762. DOI: 10.1186/2046-4053-2-10. View

15.

Evans W, Ung Y, Assouad N, Chyjek A, Sawka C . Improving the quality of lung cancer care in Ontario: the lung cancer disease pathway initiative. J Thorac Oncol. 2013; 8(7):876-82. DOI: 10.1097/JTO.0b013e31828cb548. View

16.

Bolukbas S, Eberlein M, Eckhoff J, Schirren J . Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial. Eur J Cardiothorac Surg. 2010; 39(6):995-1000. DOI: 10.1016/j.ejcts.2010.09.025. View

17.

Goffin J, Corriveau S, Tang G, Pond G . Management and outcomes of patients with chronic obstructive lung disease and lung cancer in a public healthcare system. PLoS One. 2021; 16(5):e0251886. PMC: 8128239. DOI: 10.1371/journal.pone.0251886. View

18.

Yilmaz A, Damadoglu E, Salturk C, Okur E, Yagci Tuncer L, Halezeroglu S . Delays in the diagnosis and treatment of primary lung cancer: are longer delays associated with advanced pathological stage?. Ups J Med Sci. 2008; 113(3):287-96. DOI: 10.3109/2000-1967-236. View

19.

Ajimizu H, Ozasa H, Sato S, Funazo T, Sakamori Y, Nomizo T . Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer. Sci Rep. 2021; 11(1):23677. PMC: 8654854. DOI: 10.1038/s41598-021-03139-5. View

20.

Hardavella G, Frille A, Theochari C, Keramida E, Bellou E, Fotineas A . Multidisciplinary care models for patients with lung cancer. Breathe (Sheff). 2021; 16(4):200076. PMC: 7910033. DOI: 10.1183/20734735.0076-2020. View